FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385201924> ?p ?o ?g. }

• W4385201924 endingPage "2059" @default.
• W4385201924 startingPage "2059" @default.
• W4385201924 abstract "Tumors of the parathyroid glands, when associated with PTH (parathyroid hormone) excess, display a large area of complications; in addition to the classical clinical picture of primary hyperparathyroidism (PHP), a complex panel of other symptoms/signs can be identified, including memory and cognitive impairment, chronic asthenia/fatigue, reduced muscle functionality, depressive mood, non-specific bone pain, and loss of sleep quality. The perception of quality of life (QoL) can be supplementarily enhanced by their progressive onset, which makes many patients not be fully aware of them. Their improvement was reported very early after parathyroidectomy (PTx), yet the level of statistical evidence does not qualify these non-classical elements as standalone indications for PTx. Our objective is introducing an up-to-date on QoL scores with regards to the patients diagnosed with PHP, particularly taking into consideration PHP management from baseline to post-operatory outcome, including in cases with multiple endocrine neoplasia. This is a narrative review of literature. We revised full-length papers published in English through PubMed research conducted between January 2018 and May 2023 by using the key words “quality of life” and “primary hyperparathyroidism”. We particularly looked at data on self-reported QoL (through questionnaires). We excluded from the search the studies focused on non-PTH related hypercalcemia, secondary, and/or renal/tertiary hyperparathyroidism, and vitamin D supplementation. Overall, we identified 76 papers and selected for the final analysis 16 original studies on QoL and PHP (a total of 1327 subjects diagnosed with syndromic and non-syndromic PHP). The studies with the largest number of individuals were of 92, 104, 110, 134, 159, as well as 191. A few cohorts (n = 5) were of small size (between 20 and 40 patients in each of them). Concerning the study design, except for 2 papers, all the mentioned studies provided longitudinal information, particularly the timeframe from baseline (before PTx) and after surgery. The post-operatory follow-up was of 3–6 months, but mostly between 1 and 3 years (maximum a decade of surveillance). The age of the patients varies between medians of 56, 62, 64, and 68 years. Most frequent questionnaires were SF-36, PHPQoL, and PAS. Despite not being unanimously similar, an overall reduced score of QoL in patients with PHP versus controls was registered, as well as general improvement following PTx. Variations of QoL results might have a multifactorial background from different comorbidities, studied populations, technical aspects of collecting the data, etc. QoL scores in PHP represents a complex heterogeneous picture, from their correlation with clinical features and lab assays (e.g., the level of serum calcium), the associated comorbidities (such as multiple endocrine neoplasia syndromes), up to the assessment of the QoL improvement after parathyroidectomy (PTx). While current studies do not unanimously agree on each QoL domain, the assessment of QoL might represent a supplementary argument to consider when deciding for PTx, especially in asymptomatic cases and in patients who do not fit into well-known categories of surgery candidates, according to current guidelines, thus assessing QoL in PHP is part of a current research gap. QoL evaluation in PHP remains an open issue, towards which awareness should be cultivated by both endocrinologists and surgeons. The introduction of a routine evaluation of the QoL scores in patients, as well as the selection of the most appropriate questionnaire(s), represents an open chapter thus awareness in mandatory." @default.
• W4385201924 created "2023-07-25" @default.
• W4385201924 creator A5011371139 @default.
• W4385201924 creator A5029361493 @default.
• W4385201924 creator A5068319516 @default.
• W4385201924 creator A5076106608 @default.
• W4385201924 creator A5086353697 @default.
• W4385201924 creator A5087195423 @default.
• W4385201924 date "2023-07-21" @default.
• W4385201924 modified "2023-10-17" @default.
• W4385201924 title "Neuroendocrine Parathyroid Tumors: Quality of Life in Patients with Primary Hyperparathyroidism" @default.
• W4385201924 cites W134485290 @default.
• W4385201924 cites W1952656752 @default.
• W4385201924 cites W2030645030 @default.
• W4385201924 cites W2065156538 @default.
• W4385201924 cites W2070278400 @default.
• W4385201924 cites W2089214207 @default.
• W4385201924 cites W2113750014 @default.
• W4385201924 cites W2419611626 @default.
• W4385201924 cites W2499214176 @default.
• W4385201924 cites W2533201249 @default.
• W4385201924 cites W2549626670 @default.
• W4385201924 cites W2572016296 @default.
• W4385201924 cites W2592778689 @default.
• W4385201924 cites W2756032310 @default.
• W4385201924 cites W2767257845 @default.
• W4385201924 cites W2773308676 @default.
• W4385201924 cites W2791008802 @default.
• W4385201924 cites W2792088596 @default.
• W4385201924 cites W2794115290 @default.
• W4385201924 cites W2795205356 @default.
• W4385201924 cites W2800510471 @default.
• W4385201924 cites W2808671806 @default.
• W4385201924 cites W2808793375 @default.
• W4385201924 cites W2811047527 @default.
• W4385201924 cites W2884857758 @default.
• W4385201924 cites W2886188719 @default.
• W4385201924 cites W2893222129 @default.
• W4385201924 cites W2894074914 @default.
• W4385201924 cites W2901512116 @default.
• W4385201924 cites W2905895364 @default.
• W4385201924 cites W2914347494 @default.
• W4385201924 cites W2937458509 @default.
• W4385201924 cites W2944072704 @default.
• W4385201924 cites W2954441014 @default.
• W4385201924 cites W2957507009 @default.
• W4385201924 cites W2979650061 @default.
• W4385201924 cites W2979988094 @default.
• W4385201924 cites W2998586131 @default.
• W4385201924 cites W2999028941 @default.
• W4385201924 cites W3020604574 @default.
• W4385201924 cites W3021268256 @default.
• W4385201924 cites W3022957632 @default.
• W4385201924 cites W3031432652 @default.
• W4385201924 cites W3039992069 @default.
• W4385201924 cites W3048774259 @default.
• W4385201924 cites W3049043878 @default.
• W4385201924 cites W3082498704 @default.
• W4385201924 cites W3093419226 @default.
• W4385201924 cites W3096033576 @default.
• W4385201924 cites W3108293091 @default.
• W4385201924 cites W3117299291 @default.
• W4385201924 cites W3118701661 @default.
• W4385201924 cites W3118893352 @default.
• W4385201924 cites W3130963038 @default.
• W4385201924 cites W3131637083 @default.
• W4385201924 cites W3153588975 @default.
• W4385201924 cites W3154056992 @default.
• W4385201924 cites W3155218022 @default.
• W4385201924 cites W3158565476 @default.
• W4385201924 cites W3165716721 @default.
• W4385201924 cites W3175670917 @default.
• W4385201924 cites W3179919642 @default.
• W4385201924 cites W3181727955 @default.
• W4385201924 cites W3192577503 @default.
• W4385201924 cites W3193039723 @default.
• W4385201924 cites W3199541742 @default.
• W4385201924 cites W3203388734 @default.
• W4385201924 cites W3205231319 @default.
• W4385201924 cites W3212872141 @default.
• W4385201924 cites W3213885184 @default.
• W4385201924 cites W3213906359 @default.
• W4385201924 cites W3215445035 @default.
• W4385201924 cites W3216731368 @default.
• W4385201924 cites W4205755407 @default.
• W4385201924 cites W4206627663 @default.
• W4385201924 cites W4206697660 @default.
• W4385201924 cites W4206899869 @default.
• W4385201924 cites W4213295943 @default.
• W4385201924 cites W4214922660 @default.
• W4385201924 cites W4220927864 @default.
• W4385201924 cites W4221029658 @default.
• W4385201924 cites W4226124638 @default.
• W4385201924 cites W4226136276 @default.
• W4385201924 cites W4280531638 @default.
• W4385201924 cites W4283386145 @default.
• W4385201924 cites W4284892595 @default.
• W4385201924 cites W4285386065 @default.

• next